Corcept Therapeutics, Inc. (NASDAQ:CORT)

CAPS Rating: 2 out of 5

A pharmaceutical company which is engaged in the development of drugs for the treatment of severe psychiatric and metabolic diseases.

Recs

1
Player Avatar zzlangerhans (99.76) Submitted: 5/22/2013 7:03:36 PM : Underperform Start Price: $1.89 CORT Score: +15.63

I'm back to add Corcept to my list of dirty dozens, stocks I've successfully rated at least 12 times without a losing score. The stock is mysteriously maintaining airtime despite weak and mostly stagnant Korlym revenues and a phase III trial for Korlym in psychotic depression that is now in its sixth year of attempting to enroll patients. I'm expecting the PI's of this trial to eventually die and leave their children to carry on the work. Meanwhile, the cash hoard is dwindling as the burn is in the double digits for the second quarter in a row. This won't end pretty, folks.

Featured Broker Partners


Advertisement